Hong Kong stock market anomaly | Collon Pharma (06990.HK) rose by over 11%, with its core product combination therapy for PD-L1 negative NSCLC reaching the main endpoint in Phase 3 study.
According to the Securities Times app, Colombo Biotechnology (06990.HK) rose by over 11%. As of the time of publication, it rose by 11% to HK $553, with a turnover of HK $3.56 billion.
Latest
3 m ago
